Cell Culture – Increased Production of Seasonal Influenza Vaccines
Cell culture is fast emerging as an important tool for diagnosing and clinically treating various disease such as cancer and Alzheimer’s. Companies are focusing on diversifying their cell depository and enhancing their expertise by laying major emphasis on recruitment of highly trained professionals in order to gain a competitive edge in the market. The European Collection of Authenticated Cell Cultures (ECACC) is serving the patent depository for Europe for carrying out research by acting as international depository authority. According to VF Bioscience SAS, cell culture technique is also gaining popularity in the field of food and beverages, a trend that is estimated to gain significant traction in 2017. Furthermore, cell culture are also gaining preference as an important ingredient in production of high quality plant actives.
Cell culture process can include various complications such as obtaining fully traceable botanical extracts and raw material supply. Furthermore, increasing focus on ensuring regulatory compliance related to environmental sustainability can hamper efficacy of the product. To overcome these complications in 2017, in place of using wild or field-grown plants, researchers at ABResearch srl utilized the callus cultures and cell suspension cultures for better results. According to News Medical Life-sciences, in 2017, researchers are inclined towards developing culture model that can be used in early treatment of age-related macular degeneration (AMD). AMD is the third major cause for total vision loss and also more prevalent in elderly people.
The global cell culture market was valued at US$ 12,251.3 million in 2015 and is expected to witness a robust CAGR of 7.1% during the forecast period (2016 – 2024).
High Investment in research and development by biotechnological companies
Players in the global cell culture market are making major investments in R&D to introduce advanced products used in the cell culture process owing to rise in number of application and better return on investment. Furthermore, companies are inclined towards novel product development. For instance, Biovest International, in 2009, has developed a product named AutovaxID-C, which is expected to reshape the biologic production made in the industry. The product favors the automated cell growth by replacing conventional cell growth chambers that use to acquire a large space in the laboratory. Various other factors such as increasing prevalence of chronic diseases, high importance of tissue or organ replacement with cell culture process, and increasing demand for antibody production are in turn projected to fuel cell culture market growth. Also, rise in prevalence of age-related macular degeneration is expected to underpin the cell culture market growth. Eye conditions such as diabetic retinopathy in tune with rise in number of diabetic patients globally in turn creates a conducive environment for growth of the cell culture market. AMD ranks third with a prevalence of around 8.7% globally in 2015, according to W.H.O.
Major Player’s acquisitions are expected to fuel product diversification
An advanced and schematic integration of major players, followed by various acquisitions in cell culture market is fueling the frequency of product introduction in biotechnology and molecular biology field. Also, Advancements in mammalian cell culture techniques under recombinant protein production is propelling the cell culture market to new heights. In 2013, according to MDPI AG., Journal of Pharmaceutical, between 2006 and 2011, around 15 recombinant protein therapeutics were approved by U.S. FDA. Rise in number of biologics have spurred demand for biosimilars, which in turn is expected to fuel growth of the market for cell culture in the near future. In recent times, the global cell culture market has witnessed a high level of strategic mergers and acquisitions leading to development and advancement of new cell culture products. For instance:
- In 2014, a Japan based stem cell company ReproCELL acquired Reinnervate Limited – a U.K based 3D Cell Culture Company along with a U.S. based human tissue supplier Bioserve, this is expected to help the company in the field of drug toxicity testing, neuroscience and cancer research by producing next-generation tools
- In 2013, Bio-Rad Laboratories, Inc. – manufacturer of life science research and clinical diagnostic products purchased all the assets of a division of MorphoSys AG named AbD Serotec by paying US$ 71.3 million in cash, this is expected to favor the company’s antibody manufacturing power in terms of kits and accessories
- In 2013, Evotec AG acquired Cell Culture Service GmbH – a Hamburg based company – this is expected to strengthen the company’s cell-based screening and reagent platform
Increasing number of research collaborations is expected to improve the time-to-market of highly effective and advanced products.
About CMI
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
No comments:
Post a Comment